Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Pulmonary Infections
Have you incorporated the use of MycoTOX profiles into your clinical practice and, if so, in what capacity?
Are results showing Gliotoxin and Chaetoglobosin A clinically relevant?
Related Questions
Is the combination of a negative BAL PJP PCR and normal fungitell enough to rule out PJP pneumonia in an at-risk non-HIV patient?
Do you prolong IV therapy or reduce the number of antibiotic agents for patients with pulmonary NTM infections who have completed induction IV therapy and cannot access oral antibiotic therapy due to cost?
What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
Do you integrate inhaled colistimethate sodium into existing treatment regimens for patients with bronchiectasis and PSAR infection?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
Do you treat complicated pneumonia with a drained empyema longer if Streptococcus anginosus is cultured, either in isolation or with other organisms, compared to cases in which it is not?
How do you manage a 3 cm solitary pulmonary cryptococcoma in an asymptomatic, immunocompetent, HIV-negative host?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
In light of recent measles outbreaks in the US, would you recommend an MMR booster for an immunocompetent patients born before 1957?